Serological biomarkers in autoimmune GFAP astrocytopathy

Front Immunol. 2022 Aug 2:13:957361. doi: 10.3389/fimmu.2022.957361. eCollection 2022.

Abstract

Autoimmune glial fibrillary acidic protein astrocytopathy (GFAP-A) is a newly defined meningoencephalomyelitis. The pathogenesis of GFAP-A is not well understood. The present study measured the expression levels of 200 serological cytokines in GFAP-A patients, NMOSD patients and healthy controls (HCs). The correlations between serum cytokine levels and clinical information in GFAP-A patients were analyzed. A total of 147 serological proteins were differentially expressed in GFAP-A patients compared to HCs, and 33 of these proteins were not observed in NMOSD patients. Serum levels of EG-VEGF negatively correlated with GFAP antibody titers, MIP-3 alpha positively correlated with clinical severity in GFAP-A patients, and LIGHT positively correlated with WBC counts and protein levels in the CSF of GFAP-A patients. These results suggest that GFAP and AQP4 astrocytopathy share some common pathology related to TNF signaling. Serum MIP 3 alpha may be a biomarker to assess clinical severity and a potential target for therapy of autoimmune GFAP astrocytopathy.

Keywords: CSF abnormalities; GFAP-A; MIP 3 alpha; autoantibody; autoimmune encephalitis.

MeSH terms

  • Astrocytes* / pathology
  • Autoimmune Diseases* / diagnosis
  • Autoimmune Diseases* / pathology
  • Biomarkers / blood
  • Cytokines* / blood
  • Encephalomyelitis* / diagnosis
  • Encephalomyelitis* / pathology
  • Glial Fibrillary Acidic Protein / metabolism
  • Humans
  • Intermediate Filaments

Substances

  • Biomarkers
  • Cytokines
  • Glial Fibrillary Acidic Protein